Momentum Bioscience

Specialises in developing rapid tests for bloodstream infection in patients suspected of sepsis

Momentum Bioscience’s flagship technology, SepsiSTAT®, delivers actionable, direct-from-blood results for suspected sepsis patients in hours, outpacing traditional methods.

What sets SepsiSTAT® apart? Their proprietary technology is proficient in:

Sensitive and universal microbial capture
Universal detection of viable microorganisms
Organism profiling

These capabilities inform clinicians with critical insights to improve patient outcomes, optimize antibiotic management, and combat antimicrobial resistance, an escalating issue which poses significant threat to human health.

Founded in 2008, they are driven by a mission to transform diagnostic timelines for critically-important clinical specimens in hospital microbiology laboratories. Backed by founders, business angels, and venture capital, they operate from their headquarters near Cardiff and their R&D facility at Milton Park, near Oxford, UK. Momentum Bioscience is actively seeking partners for joint commercialisation to bring these game-changing solutions to patients worldwide.